Modification of liposomes composed of a cationic lipid TMAG and an anionic lipid DSPG with a PEGylated lipid based on the investigation of lipid structures

Hohokabe, Miyuki; Higashi, Kenjirou; Yamada, Yurina; Fujimoto, Takao; Tokumoto, Taisei; Imamura, Hiroshi; Morita, Takeshi; Limwikrant, Waree; Moribe, Kunikazu

doi:10.1016/j.colsurfa.2022.130891

Cited by 3 publications

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Through PEGylation, drugs are endowed with a hydrophilic layer, altering their hydrophilicity and size to allow them to penetrate the mucus layer. PEG-modified liposomes can reduce the rigidity of the lipid bilayer, provide positive curvature to the lipid bilayer, stabilize the dispersion of liposomes in water by site-blocking, and also enhance the internalization and anticancer effects of PEGnanoliposome, overcoming the lack of enhanced permeability and retention effect (EPR) action in hematological malignancies and improving therapeutic efficacy [11,12]. Liu developed an azithromycin-containing liposome for the treatment of MRSA infections and found that it did not exhibit significant side effects or toxicity in mice but was able to significantly reduce the bacterial count in a mouse model of MRSA infection and had high antibacterial activity [13].…”

Section: Introductionmentioning

confidence: 99%

Polyethylene Glycol-Modified Cationic Liposome as a Promising Nano Spray for Acute Pneumonia Treatment

Wang,

Chen,

Zhang

et al. 2024

Polymers

View full text Add to dashboard Cite

Acute pneumonia (AP), triggered primarily by pathogens like bacteria and viruses, is a leading cause of human mortality. Ribavirin, a broad-spectrum antiviral agent, plays a pivotal role in the treatment of AP. However, its therapeutic use is hindered by the need for high dosages and the associated cardiac and hepatic toxicities. In this study, we synthesized polyethylene glycol-modified cationic liposomes to encapsulate ribavirin (RBV-PCL) and formulated it into a spray, aiming to enhance the effectiveness of RBV through respiratory administration. Lipopolysaccharide (LPS), a compound known to induce AP models in animals, was utilized in our research. Successfully, we established an acute pneumonia model in mice using aerosol inhalation. Through animal experiments, we investigated the therapeutic effects of RBV-PCL on mice with AP. In vivo studies revealed promising results. RBV-PCL effectively prolonged the survival of mice with AP, significantly reduced the levels of inflammatory markers such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), and inhibited the infiltration of neutrophils in the lungs and spleens of mice. These findings suggest that RBV-PCL can effectively suppress the inflammatory response in mice with AP, thus holding significant potential as a novel therapeutic approach for the treatment of acute pneumonia.

show abstract

Section: Introductionmentioning

confidence: 99%